Neogenomics, Inc.
NEO
$8.75
$0.091.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 186.67M | 190.17M | 187.80M | 181.33M | 168.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 186.67M | 190.17M | 187.80M | 181.33M | 168.04M |
| Cost of Revenue | 105.81M | 106.83M | 107.35M | 104.47M | 94.79M |
| Gross Profit | 80.86M | 83.34M | 80.45M | 76.86M | 73.25M |
| SG&A Expenses | 88.77M | 86.65M | 86.95M | 91.36M | 87.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 204.11M | 202.65M | 202.99M | 204.86M | 192.88M |
| Operating Income | -17.44M | -12.48M | -15.19M | -23.53M | -24.84M |
| Income Before Tax | -17.58M | -12.41M | -26.39M | -45.82M | -25.66M |
| Income Tax Expenses | -472.00K | -2.53M | 740.00K | -724.00K | 266.00K |
| Earnings from Continuing Operations | -17.11M | -9.88M | -27.13M | -45.09M | -25.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.11M | -9.88M | -27.13M | -45.09M | -25.92M |
| EBIT | -17.44M | -12.48M | -15.19M | -23.53M | -24.84M |
| EBITDA | -1.03M | 3.91M | 1.24M | -6.26M | -7.11M |
| EPS Basic | -0.13 | -0.08 | -0.21 | -0.35 | -0.20 |
| Normalized Basic EPS | -0.08 | -0.06 | -0.07 | -0.11 | -0.11 |
| EPS Diluted | -0.13 | -0.08 | -0.21 | -0.35 | -0.20 |
| Normalized Diluted EPS | -0.08 | -0.06 | -0.07 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 129.17M | 128.65M | 128.42M | 127.95M | 127.38M |
| Average Diluted Shares Outstanding | 129.17M | 128.65M | 128.42M | 127.95M | 127.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |